Literature DB >> 28586335

Biology and evolution of poorly differentiated neuroendocrine tumors.

David S Rickman1,2,3, Himisha Beltran1,3,4, Francesca Demichelis1,5,6, Mark A Rubin1,2,3.   

Abstract

Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis of their site of origin. This Perspective focuses on advances in our understanding of the tumorigenesis and treatment of poorly differentiated neuroendocrine tumors. Recent evidence from sequencing indicates that, although neuroendocrine tumors can arise de novo, they can also develop as a result of lineage plasticity in response to pressure from targeted therapies. We discuss the shared genomic alterations of these tumors independently of their site of origin, and we explore potential therapeutic strategies on the basis of recent biological findings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28586335     DOI: 10.1038/nm.4341

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  138 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.

Authors:  Xuehong Deng; Han Liu; Jiaoti Huang; Liang Cheng; Evan T Keller; Sarah J Parsons; Chang-Deng Hu
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

4.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

5.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

7.  Neuroendocrine differentiation in human prostatic tumor models.

Authors:  M A Noordzij; W M van Weerden; C M de Ridder; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

8.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

Review 9.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

10.  N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

Authors:  John K Lee; John W Phillips; Bryan A Smith; Jung Wook Park; Tanya Stoyanova; Erin F McCaffrey; Robert Baertsch; Artem Sokolov; Justin G Meyerowitz; Colleen Mathis; Donghui Cheng; Joshua M Stuart; Kevan M Shokat; W Clay Gustafson; Jiaoti Huang; Owen N Witte
Journal:  Cancer Cell       Date:  2016-03-31       Impact factor: 31.743

View more
  66 in total

Review 1.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Authors:  Erik S Knudsen; Steven C Pruitt; Pamela A Hershberger; Agnieszka K Witkiewicz; David W Goodrich
Journal:  Trends Cancer       Date:  2019-04-30

2.  TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.

Authors:  Alexandra M Blee; Yundong He; Yinhui Yang; Zhenqing Ye; Yuqian Yan; Yunqian Pan; Tao Ma; Joseph Dugdale; Emily Kuehn; Manish Kohli; Rafael Jimenez; Yu Chen; Wanhai Xu; Liguo Wang; Haojie Huang
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

3.  EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

Authors:  James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

Review 4.  The Dual Roles of the Atypical Protein Kinase Cs in Cancer.

Authors:  Miguel Reina-Campos; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cancer Cell       Date:  2019-08-29       Impact factor: 31.743

5.  Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Authors:  A J Armstrong; E S Antonarakis; M-E Taplin; W K Kelly; H Beltran; K Fizazi; W L Dahut; N Shore; S Slovin; D George; M A Carducci; P Corn; D Danila; R Dreicer; E Heath; D Rathkopf; G Liu; D Nanus; M Stein; M R Smith; C Sternberg; G Wilding; P S Nelson; S Halabi; P Kantoff; N W Clarke; C P Evans; A Heidenreich; N Mottet; M Gleave; M J Morris; H I Scher
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

6.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.

Authors:  Nikolas G Balanis; Katherine M Sheu; Favour N Esedebe; Saahil J Patel; Bryan A Smith; Jung Wook Park; Salwan Alhani; Brigitte N Gomperts; Jiaoti Huang; Owen N Witte; Thomas G Graeber
Journal:  Cancer Cell       Date:  2019-07-08       Impact factor: 31.743

Review 7.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 8.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Authors:  Alastair H Davies; Himisha Beltran; Amina Zoubeidi
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

9.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Alessandro Romanel; Vincenza Conteduca; Nicola Casiraghi; Michael Sigouros; Gian Marco Franceschini; Francesco Orlando; Tarcisio Fedrizzi; Sheng-Yu Ku; Emma Dann; Alicia Alonso; Juan Miguel Mosquera; Andrea Sboner; Jenny Xiang; Olivier Elemento; David M Nanus; Scott T Tagawa; Matteo Benelli; Francesca Demichelis
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 10.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.